Product Name: Mirabegron CAS NO:223673-61-8
Chemical & Physical Properties:
Appearance : White to off-white powder
Boiling Point:690℃ at 760 mmHg
Flash Point: 371.1℃
Mirabegron was developed by Japan's Astellas Pharmaceutical Company, and was listed in Japan on September 16, 2011, and was approved by the U.S. Food and Drug Administration (FDA) on June 28, 2012. Treatment of overactive bladder (OAB) in adults. Mirabegron is the first β3 adrenergic receptor agonist drug used for the treatment of overactive bladder, and its successful listing fills the gap in the treatment of overactive bladder.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.